Li Juan, Zhang Xia
Department of Dermatology, Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, Jilin 130021, China.
Department of Dermatology, Yangling Demonstration Zone Hospital, Xianyang, Shaanxi 712100, China.
Emerg Med Int. 2022 Aug 25;2022:1194355. doi: 10.1155/2022/1194355. eCollection 2022.
The study aimed to analyze the effectiveness and safety of microplasma beam in the treatment of facial depression scars.
106 patients with facial depression scars treated in the hospital between January 2017 and September 2021 were selected as the observation subjects. According to different treatment methods, the patients were divided into the control group (receiving ultrapulsed carbon dioxide lattice laser treatment, = 51) and the observation group (undergoing plasma beam treatment, = 55). The two groups were treated for 6 months, and the treatment effects were compared between the two groups. The Visual Analogue Scale (VAS) was used to compare the pain between the two groups, and the duration of pain and the time of scab shedding were recorded. The improvement of scars was compared between the two groups according to the Evaluation Clinique des Cicatrices d' Acne (ECCA), and the adverse reactions during treatment were compared between the two groups.
A clinical effective rate of 94.55% in the observation group was higher than a clinical effective rate of 82.35% in the control group ( < 0.05). The VAS score in the observation group was lower than that in the control group, and the pain duration and the scab shedding time were shorter than those in the control group ( < 0.05). ECCA scores in the observation group after twice and 3 times of treatments were lower than those in the control group ( < 0.05). The total incidence rate of adverse reactions of 10.91% in the observation group was lower, whereas it was 25.49% in the control group ( > 0.05).
Plasma beam has a significant efficacy in the treatment of facial depressed scars, and it has mild pain, quick recovery, and high safety. The clinical trial registration number is T2017081.
本研究旨在分析微等离子束治疗面部凹陷性瘢痕的有效性和安全性。
选取2017年1月至2021年9月在本院接受治疗的106例面部凹陷性瘢痕患者作为观察对象。根据治疗方法的不同，将患者分为对照组（接受超脉冲二氧化碳点阵激光治疗，n = 51）和观察组（接受等离子束治疗，n = 55）。两组均治疗6个月，比较两组的治疗效果。采用视觉模拟评分法（VAS）比较两组的疼痛程度，并记录疼痛持续时间和结痂脱落时间。根据痤疮瘢痕临床评估（ECCA）比较两组瘢痕的改善情况，并比较两组治疗期间的不良反应。
观察组临床有效率为94.55%，高于对照组的82.35%（P < 0.05）。观察组VAS评分低于对照组，疼痛持续时间和结痂脱落时间短于对照组（P < 0.05）。观察组治疗2次和3次后的ECCA评分低于对照组（P < 0.05）。观察组不良反应总发生率为10.91%，低于对照组的25.49%（P > 0.05）。
等离子束治疗面部凹陷性瘢痕疗效显著，疼痛轻，恢复快，安全性高。临床试验注册号为T2017081。
